• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Helius Medical Technologies Inc.

    8/15/22 6:00:57 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email
    SC 13G 1 ea164355-13gintra_helius.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Helius Medical Technologies, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

     

    (Title of Class of Securities)

     

    42328V603

     

    (CUSIP Number)

     

    August 5, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a. ☐ Rule 13d-1(b)
    b. ☒ Rule 13d-1(c)
    c. ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 8 

     

     

    CUSIP No. 42328V603  

     

    1.

    Names of Reporting Persons.

     

    Mitchell P. Kopin

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b)

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States of America

    Number of
    Shares

    Beneficially

    Owned by

    Each
    Reporting Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,500,000

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,500,000

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,500,000 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    8.4% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    IN; HC

     

    Page 2 of 8 

     

     

    CUSIP No. 42328V603  

     

    1.

    Names of Reporting Persons.

     

    Daniel B. Asher

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b)

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States of America

    Number of
    Shares

    Beneficially

    Owned by

    Each
    Reporting Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,500,000

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,500,000

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,500,000 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    8.4% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    IN; HC

     

    Page 3 of 8 

     

     

    CUSIP No. 42328V603  

     

    1.

    Names of Reporting Persons.

     

    Intracoastal Capital LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b)

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of
    Shares

    Beneficially

    Owned by

    Each
    Reporting Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,500,000

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,500,000

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,500,000 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    8.4% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    Page 4 of 8 

     

     

    Item 1.

     

    (a) Name of Issuer

     

    Helius Medical Technologies, Inc. (the “Issuer”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    642 Newtown Yardley Road, Suite 100

    Newtown, PA, 18940

     

    Item 2.

     

    (a) Name of Person Filing

     

    (b) Address of Principal Business Office or, if none, Residence

     

    (c) Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d) Title of Class of Securities

     

    Common Stock, $0.001 par value per share, of the Issuer (the “Common Stock”).

     

    (e) CUSIP Number

     

    42328V603

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Page 5 of 8 

     

     

    Item 4. Ownership.

     

    (a) and (b):

     

    (i) Immediately following the execution of the securities purchase agreement with the Issuer on August 5, 2022 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on August 9, 2022), each of the Reporting Persons may have been deemed to have beneficial ownership of 465,836 shares of Common Stock, which consisted of (i) 450,000 shares of Common Stock to be issued to Intracoastal at the consummation of the transaction contemplated by the SPA and (ii) 15,836 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the consummation of the transaction contemplated by the SPA (“Intracoastal Warrant 1”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 4,197,189 shares of Common Stock outstanding prior to the execution of the SPA as reported to the Reporting Persons by the Issuer, plus (2) 450,000 shares of Common Stock to be issued to Intracoastal at the consummation of the transaction contemplated by the SPA and (3) 15,836 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 534,164 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock, (II) 1,500,000 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the consummation of the transaction contemplated by the SPA (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock, (III) 6,868 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (IV) 29,520 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 4”) because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 2,536,388 shares of Common Stock.

     

    (ii) As of the close of business on August 12, 2022, each of the Reporting Persons may have been deemed to have beneficial ownership of 2,500,000 shares of Common Stock, which consisted of (i) 1,000,000 shares of Common Stock held by Intracoastal and (ii) 1,500,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock represented beneficial ownership of approximately 8.4% of the Common Stock, based on (1) 27,794,797 shares of Common Stock outstanding following the consummation of the transaction contemplated by the SPA as reported by the Issuer, plus (2) 550,000 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 1 and (3) 1,500,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 6,868 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (II) 29,520 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4 because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 2,536,388 shares of Common Stock.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:        0        .

     

    (ii) Shared power to vote or to direct the vote:         2,500,000        .

     

    (iii) Sole power to dispose or to direct the disposition of        0        .

     

    (iv) Shared power to dispose or to direct the disposition of        2,500,000        .

     

    Page 6 of 8 

     

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 7 of 8 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: August 15, 2022

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher

     

      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 8 of 8

     

    Get the next $HSDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      1/8/25 4:10:32 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Perkins Sherrie L

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      1/8/25 4:10:39 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Favit-Van Pelt Antonella R.

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      1/8/25 4:10:36 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device

      - CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an additional authorized claim for payment for the PoNS Device from CignaHealth. CignaHealth becomes the fifth major payer to authorize claims for payment for the PoNS Device

      6/16/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

      -PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data previously reported- NEWTOWN, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Deborah Backus, PT, Ph.D., FACRM- Vice President of Research and Innovation at Atlanta's Shepard Center presented the positive results from the PoNS Therapeutic Experience Program, or

      6/12/25 6:59:59 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

      -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

      6/11/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    SEC Filings

    See more
    • Helius Medical Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      6/23/25 8:30:26 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies Inc. filed SEC Form 8-K: Leadership Update

      8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      6/20/25 5:15:24 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B4 filed by Helius Medical Technologies Inc.

      424B4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      6/5/25 8:00:49 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Helius Medical Tech downgraded by Noble Capital Markets

      Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

      11/15/21 10:55:44 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Noble Capital Markets initiated coverage on Helius Medical with a new price target

      Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00

      3/24/21 8:02:45 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies

      LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy

      2/12/21 8:21:57 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

      4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      2/15/24 4:06:00 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/15/23 7:00:42 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/4/23 8:30:12 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care